You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
創勝集團-B(06628.HK)獲選於2022年國際腎臟病學會補體相關腎病前沿會議上展示TST004臨牀前數據
格隆匯 06-28 08:11

格隆匯6月28日丨創勝集團-B(06628.HK)發佈公吿,其獲選於意大利貝加莫舉行的2022年國際腎臟病學會補體相關腎病前沿會議上展示TST004臨牀前數據。

TST004是一種靶向甘露聚糖結合凝集素關聯絲氨酸蛋白酶2(MASP2)的人源化單克隆抗體,被設計為可防止由凝集素通路補體激活介導的炎症及組織損傷。MASP2(甘露聚糖結合凝集素關聯絲氨酸蛋白酶2)是補體激活凝集素通路啟動的一種關鍵酶。研究顯示,凝集素通路激活促進多種人類疾病的發生,如免疫球蛋白A型腎病(IgAN)、造血幹細胞移植相關血栓性微血管病(HSCT-TMA)。因此,抑制MASP2可能是與凝集素通路激活相關的疾病的潛在治療方法。

“免疫球蛋白A型腎病(IgAN)是全球高發性疾病,也是醫療需求缺口巨大的領域。臨牀前數據為TST004進一步評估為補體依賴性疾病(如免疫球蛋白A型腎病(IgAN)及造血幹細胞移植相關血栓性微血管病(HSCT-TMA))的潛在治療方法提供了令人信服的科學原理”,公司首席執行官錢雪明博士表示,“我們正在努力將TST004推進至臨牀開發階段,希望能夠惠及更多受急切醫療需求缺口影響的患者。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account